Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Kelly Clarkson's Ex-Husband Brandon Blackstock Dead At 48 What You're Really Eating When You Order Taco Bell Helicopter ...

David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business ...

Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and ...

Sales grew 38% year over year, driven by volume growth from weight-loss and diabetes drugs Zepbound and Mounjaro, Lilly said.

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.

STORY: U.S. stocks ended mixed on Thursday, with the Dow dropping about half a percent, the S&P 500 closing essentially flat, ...

Drugmaker Eli Lilly said Thursday that things are looking good for their latest weight loss drug that would be available as a ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.